...
Date | Requested action | Requester(s) | Response required by: | Comments |
|---|---|---|---|---|
| 19 March 2020 | Please state the preferred response for implementers in your country |
| Please post your final responses in the Country response table below. Discussion comments can be made as comments. |
...
| Country | Date | Response | |||||
|---|---|---|---|---|---|---|---|
| Australia | 25/03/2020 | We support this. I think the revision to FSN without churning the concept is acceptable. The use of a contrast agent would seem to be implicit in these procedures. For those that don't specify CT/fluoroscopic, I presume no change? (as could be Radionuclide). One side note is that 385420005|Contrast media (substance)| is arguably a role... | |||||
| Norway | 27/03/2020 | Agree to change. | |||||
| Canada | 2020-04-08 | Fluoroscopic Angiography- for the most part uses contrast to visualize the anatomy relevant to the procedure. There are instances where it is not always used. ie. portacath insertion, or permacath insertion. However, there are times where of course this is not always feasible as there may be trouble accessing the initial vein, so contrast is used to confirm access. Otherwise we agree with the proposed change. | |||||
| US | 2020-04-08 | OK | |||||
| UK | 09-04-2020 | With apologies for the delay in replying, but we are obviously having to prioritise COVID-19 work. This impacts the SNOMED CT maps to 428 National Interim Imaging Procedures used in every imaging department in the UK, so we were prefer revision to the FSN without inactivation. However this also impacts our NICIP-OPCS mapping table. We are currently investigating the impact of this, and will get back as soon as possible. Our preference would also be to contact our imaging community about this change if time can be given for this to be done? Though in the present circumstances of COVID-19 these people are probably very busy and may not respond quickly. | |||||
| Member countries without a CMAG rep |
...